TruthArchive.ai - Related Video Feed

Warburg hypothesized that lowering blood sugar restricts fuel to tumors. Research shows cancer cell mitochondria are damaged, impairing their ability to generate energy through oxygen. Cancer cells ferment, obtaining energy without oxygen, similar to ancient organisms before atmospheric oxygen. They primarily use glucose, and also glutamine, for fermentation. Targeting tumors by depriving them of glucose and glutamine can kill them without toxicity. This approach is called the press pulse therapeutic process. The field doesn't recognize this because of the prevailing dogma that cancer is a genetic disease. This dogma prevents consideration of alternative approaches and can affect funding. Despite published papers explaining this, the understanding remains limited within the field, though it resonates with the general public.

Some antiparasitic drugs like mabendazole and ivermectin have shown effectiveness against certain cancers. Combining these drugs with others has led to the disappearance of solid tumors in some patients. It's not a single drug but a combination approach that yields results.

Fenbendazole is presented as not simply a dog dewormer, but a drug with broad veterinary use and potential human relevance. It binds to tubulin in parasites, preventing movement and glucose use, causing death. It treats nematodes, flukes, and protozoa like Giardia, across species from cattle to bears. It is not widely approved for human use, unlike its cousins mebendazole and albendazole, which are approved for people; fenbendazole is approved for animals. In 2016, Joe Tippins, with small cell lung cancer at MD Anderson, after hospice, tried fenbendazole on advice of a large-animal vet; within three months his scans were clean and remain so. Mechanistically, fenbendazole disrupts microtubules, halting mitosis and triggering apoptosis, arrests at G2, upregulates p53 and p21, and inhibits Hexokinase II, reducing glycolysis. It may enhance immune recognition and revert tumor-associated macrophages from M2, contributing to tumor control.

I found over 100 scientific papers showing Ivermectin's potential against cancer, primarily from preclinical studies. Researchers are puzzled by how this anti-parasitic drug, which has been effective for decades, can also treat cancer. Ivermectin is off patent, meaning there's little financial incentive for big pharma to invest in its research. Notably, Ivermectin can kill cancer stem cells, reverse chemotherapy resistance, and enhance the effectiveness of both chemotherapy and radiation. Patients combining Ivermectin with these treatments have shown remarkable results, including significant tumor reductions. After two years of research, I now treat over 1,000 cancer patients with Ivermectin and other anti-parasitic drugs. The recent mention by Mel Gibson about friends curing stage 4 cancer with these treatments highlights the growing awareness of this approach.

Fermentation is the process of obtaining energy (ATP) without oxygen. Cancer cells, regardless of type (glioblastoma, lung, colon, breast, bladder), utilize a similar mechanism: fermentation, or energy production without oxygen. The primary fuels for this fermentation are the sugar glucose and the amino acid glutamine. Therefore, to kill cancer cells, it's necessary to deprive them of these fermentable fuels.

Fenbendazole is an overlooked cancer drug with at least 12 proven anti-cancer mechanisms. It disrupts microtubule polymerization, induces cell cycle arrest, blocks glucose transport, increases tumor suppressor levels, inhibits cancer cell viability, migration, and invasion, induces apoptosis, autophagy, and necrosis, and inhibits angiogenesis and drug resistance. Mebendazole, a similar drug, is already approved by the FDA and in clinical trials for brain and colon cancers. However, there are no Fenbendazole clinical trials for cancer, likely because it is cheap, safe, and effective. Big pharma may not see a profit margin in it, which raises concerns about their motives. This highlights the issue of a society designed to make people sick, with pharmaceutical companies profiting from remedies.

Warburg hypothesized that restricting fuel to a tumor by lowering blood sugar could be effective. Research shows that cancer cell mitochondria are damaged, preventing energy generation through oxygen use. Cancer cells ferment, using an ancient pathway to grow without oxygen, similar to organisms before atmospheric oxygen. ATP, or energy, is essential for cell survival and growth. Cancer cells obtain energy through fermentation, primarily using glucose and glutamine. Depriving tumor cells of these fuels can kill them. This approach forms the basis of a therapeutic process to kill cancer cells without toxicity. The field's adherence to the dogma that cancer is a genetic disease hinders the recognition and acceptance of these findings. This dogma prevents consideration of alternative metabolic approaches, potentially influenced by funding priorities. Despite challenges in acceptance within the field, the public understands the implications of this research.

"We get sick because of three things primarily. We get sick because of electromagnetic radiation, because of poisons that they put into the environment, and because of parasites." "I found about about five or six years ago, underground group of people that were using Fenbendazole in these things for cancer, and it was working." "He had throat cancer." "So his wife searched around the internet and found this story about the Fenbendazole and started treating him using the protocol." "Isn't it interesting that parasitic medication also treats cancer?" "I think it's not that it also treats cancer, it's that cancer is parasites."

Fenbezodizole, a potential miracle drug for cancer, has at least 12 proven anti-cancer mechanisms of action. It is speculated that big pharma fears it due to its low cost. The speaker hopes that Flint is aware of this and examines it. There has been some reaction to this discovery, and it is revealed that a similar drug in the same family, menbendazole, has already been approved by the FDA and is in clinical trials for brain and colon cancers. The lack of clinical trials for Fenbezodizole is attributed to its low cost, safety, and effectiveness. Big pharma's lack of interest in it is seen as an obstacle to people accessing potentially life-saving treatments. The speaker suggests that society is designed to make people sick, allowing big pharma to profit from their remedies.

Cancers are often classified by location and pathological type, leading to the belief that treatments must be specific to each cancer. This view is based on the somatic mutation theory, which highlights the diverse mutations found in different cancers, even within the same tumor. However, research reveals a commonality: all cancers ferment for energy. This led to an investigation of the ultrastructure of cancer cells, including lung, breast, colon, pancreatic, bladder, and blood cancers. The commonality was abnormalities in the number, structure, and function of mitochondria across all major cancers. Since structure determines function, abnormal mitochondrial structure implies diminished function, leading to fermentation. Cancers then rely on glucose and glutamine fermentation. Thus, despite differing appearances and genomic profiles, cancers share metabolic similarities and may respond to a unified metabolic therapy strategy.

The speaker presents a theory of cancer origin and management centered on the idea that cancer cells are cells hovering near death and severely limited in their capacity for survival, in contrast to normal cells in different organs that can flexibly generate and use energy. The core claim is that cancer cells are tightly linked to fermentation-based energy, whereas healthy cells have broader metabolic options. Based on this framework, the speaker outlines a staged strategy to “kill cancer cells” by manipulating energy metabolism. First, the speaker advises reducing the glucose–ketone index (GKI) to close to 2.0 or below 1.0, asserting that this shift will begin to kill cancer cells. To achieve this, the speaker recommends a zero-carbohydrate diet for about ten days, with monitoring to observe the GKI stair-stepping downward in the right direction. The implication is that lowering GKI shifts the body's energy utilization away from glucose toward alternative fuels in a way that pressures cancer cells. Next, after the initial dietary period, the speaker suggests transitioning to water-only fasting. During or after this fasting phase, a “battery of drugs” is introduced—specifically repurposed drugs described as pounding the glutamine pathway and further lowering glucose. The speaker asserts that these tumor cells are “toast” under this dramatic metabolic change, implying that cancer cells cannot cope with the combined stress on glucose and glutamine metabolism. The speaker goes on to claim that, in addition to direct metabolic pressure on tumor cells, healthy body cells compete with tumor cells, effectively starving the cancer cells even more. A further claimed mechanism is “autolytic cannibalism,” where the body reportedly targets tumor cells and uses them as fuel for healthier cells, enhancing the body's ability to combat cancer. The speaker characterizes this process as “evolutionary biology in action,” emphasizing a natural, systemic shift in energy use and cellular competition that favors normal cells over cancer cells. Overall, the presentation outlines a sequential, metabolism-driven approach to cancer treatment: first drive the GKI downward through a zero-carb diet, then implement water-only fasting with a combination of repurposed drugs to suppress glutamine utilization and further reduce glucose availability, with the expectation that tumor cells will be overwhelmed while healthy cells survive and even utilize tumor cells for fuel in a process described as autolytic cannibalism and competitive starvation.

The speaker notes that certain parasite medications show strong potential in targeting glutamine metabolism in cancer. Specifically, the Benzazole class and Fenbendazole are highlighted as medications being explored in this context. The central question addressed is why a parasite medication might be effective against cancer cells. The answer given is that parasites and cancer cells share a common metabolic pathway: glutaminolysis. This pathway involves substrate-level phosphorylation in the mitochondria, and it is the same metabolic process being targeted. The speaker references a recent publication related to this mechanism, described as a paper with Derek’s big paper, indicating that the concept and supporting data have been recently published. The emphasis is on the idea that inhibiting glutaminolysis could disrupt a critical energy and biosynthetic pathway that both parasite-infected cells and cancer cells rely upon, potentially providing a therapeutic avenue. The discussion reinforces that the medications under consideration—Benzazole compounds and Fenbendazole—are being actively developed or tested for their ability to interfere with this shared mitochondrial metabolic route. Additionally, the speaker connects the effectiveness of these parasite drugs to the broader principle that targeting a common metabolic vulnerability in cancer cells may yield translational opportunities from antiparasitic strategies. The overall point is that leveraging parasite medicines, which may disrupt glutaminolysis, could offer a way to impair cancer cell metabolism through mitochondrial substrate-level phosphorylation, a mechanism now supported by recent publication activity. The takeaway is that there is ongoing work to validate the approach of repurposing parasite-targeting drugs to exploit the glutaminolysis pathway in cancer, with empirical support emerging from the referenced Derek-associated publication.

Ivermectin and mebendazole may disrupt cancer cell metabolism and glioma growth. Ivermectin blocks tumor cells from generating energy through oxidative phosphorylation, inhibits cancer stem cells, and disrupts glucose uptake. Mebendazole interferes with microtubule formation in glioma cells, induces apoptosis, and crosses the blood brain barrier. These drugs are backed by emerging science and used in terrain-based cancer protocols. When combined with fasting, oxygen therapy, and targeted nutrition, they may help flip the metabolic switch and support the body's natural healing power. The speaker claims this is how they overcame stage four brain cancer. The speaker is offering their complete healing protocol for free to those who comment "protocol."

I am presenting a case series of three patients whose cancers went into remission after taking the antiparasitic drug fenbendazole, as detailed in a paper published in Clinical Oncology Case Reports. Fenbendazole is a veterinary medicine that interferes with microtubule formation during cell division, which may inhibit cancer cell proliferation. This suggests it could be a safe and effective option for cancer treatment. There is an urgent need for drug regulators to consider repurposing fenbendazole for human use, especially since other safe treatments have been approved quickly. Further research is necessary to establish its role as a chemotherapy option. The paper indicates that these three patients experienced significant improvement in their cancer conditions. For more details, refer to the full paper.

Speaker 0: When you put the patient into nutritional ketosis, it opens up a whole new array of drugs that may have been considered ineffective. This is the field of repurposing drugs: once in this new physiological state, things thought to be ineffective can become super effective. This is a whole new field that will emerge as the results get shared more. You mentioned mebendazole in your talk as well. Does that have a glutamine-blocking aspect to it? Yes, that's in our paper too. Parasite medications. I don’t know about ivermectin because there was a lot of political stuff around that, so I told the lab we’re not going to do that to avoid wrath from somebody. Albendazole, fenbendazole, I said, why the hell do people have taken that? You hear people say, well, it got rid of my cancer with this and that. So I did a dive on it and asked why parasite medications work against cancer cells. It turns out that the parasites use mitochondrial substrate level phosphorylation in the tissue. Albendazole and fenbendazole kill these parasites, so I tried them on cancer cells, and sure as hell, they target the mitochondrial substrate and glycolysis. So we have a mechanism now why parasite medications are working. But cancer is not a parasite. All these people say cancer is a parasite – it’s not. Parasites and tumors use a common metabolic pathway, and a drug that works against parasites can be very effective against cancer, and that’s what we begin to see, especially under nutritional ketosis. Right? Speaker 1: Ivermectin actually works on the mitochondrial cell death pathway, the BCL2 Bax BAD pathway, so it actually helps push the cell death pathway.

A veterinarian told me a story about a scientist who implanted cancer in mice and then cured them of intestinal parasites using a drug called Fenbendazole. The scientist later developed glioblastoma but cured herself by taking Fenbendazole. Inspired by this, I started taking Fenbendazole too, which is a dry powder used to deworm dogs. I mix it with yogurt or a smoothie and sometimes just swallow it. It's a veterinary medicine, so I don't need a prescription. I also added curcumin, CBD oil, and vitamin E to my regimen. This protocol is now known as the Joe Tippen's protocol.

Fenbezodizole, a potential miracle drug for cancer, has at least 12 proven anti-cancer mechanisms of action. It is speculated that big pharma fears this drug due to its low cost. There is hope that Flint, who is mentioned in the conversation, will be interested in examining it. The drug disrupts microtubule polymerization, induces cell cycle arrest, blocks glucose transport, increases tumor suppressor levels, inhibits cancer cell viability and migration, induces autophagy, apoptosis, and necrosis, and inhibits angiogenesis and drug resistance. A similar drug, menbendazole, is already approved by the FDA and in clinical trials for brain and colon cancers. The lack of clinical trials for Fenbezodizole may be due to its low cost and effectiveness. Big pharma's lack of interest in it is seen as preventing people from accessing potentially beneficial treatments. The conversation also touches on the idea that society is designed to make people sick, with big pharma profiting from remedies.

Speaker 0: I have three friends. All three of them had stage four cancer. All three of them don't have cancer right now at all. And they had some serious stuff going on. And what did they take? Yep. Jesus. They took some what you've heard they've taken. Speaker 1: Ivermectin. Fenbendazole. Fenbendazole. Yeah. Speaker 0: That's it. Speaker 1: Yeah. I'm hearing that a lot. Speaker 0: They drank hydrochloride something or other? There's studies on Speaker 1: that now where people have proven that they've Speaker 0: drinking methylene blue and stuff Speaker 1: like that. Yeah. Methylene blue, which was a fabric dye. Speaker 0: Yeah. Yeah. It was a textile dye, and now they find it has profound effects on your mitochondria. Yep. Yeah. Speaker 0: This stuff works, man. There's a lot of stuff that does work, which is very strange Speaker 1: Mhmm. Because, again, it's profit. When you when you hear about things that are demonized and that that turn out to be effective, you always wonder, well, what is going on here? Mhmm. How is how is our medical institutions how have they failed us so that things that do cure you are not promoted because they're not profitable?

Cancer originated from damage to mitochondria, forcing the cell into a fermentation mechanism to survive. The two fermentation fuels that drive the majority, if not all cancers, are a sugar fermentation and an amino acid fermentation. Without glucose and glutamine, no cancer cell can survive. All of the major chronic diseases that we are currently suffering from are the result of excessive amounts of carbohydrates in the diet. The very treatments that are used, radiation as well as temozolomide, they free up massive amounts of glucose and glutamine in the tumor microenvironment, making long term survival very, very rare. I published a clear paper on how the radiation breaks apart the glutamine–glutamate cycle in the brain, freeing up massive amounts of glutamine. Steroids they give these patients increases blood sugar. The two fuels necessary for causing cancer cells to grow out of control are made available in abundant quantities by the very treatments that we're doing to these patients. And cancer cells can't burn ketones or fats. They only can burn glucose and glutamine. And actually, we still don't know the mechanism by which ketogenic diets block epilepsy, but it became crystal clear as how this diet could stop cancer growth.

The speaker describes a medical situation in which cancer had spread extensively: “In my neck, my liver, my bladder, my pancreas, and in my bones from head to toe.” He notes that when small cell lung cancer metastasizes this far, the prognosis is extremely poor, stating that “Life expectancy goes below one percent.” Shortly after, he received a call from a large animal veterinarian who shared a remarkable anecdote involving cancer research at Merck Animal Health on the veterinary medicine side. The veterinarian explained that a scientist working there had been implanting cancer in mice for research, and as a result her entire mouse population developed intestinal parasites. According to the story, the scientist administered fenbendazole, the drug commonly used to treat parasites in animals. Remarkably, not only did the drug save the mice from dying of intestinal parasites, but weeks later it appeared to cure the mice of cancer as well. The speaker recounts this as a concise answer to the question at hand about possible treatments. Motivated by this anecdote, the speaker began taking fenbendazole himself, starting the day after receiving the veterinarian’s account. He reports that “three and a half months later” he was all clear of cancer. In summary, the speaker connects a dire prognosis for widespread metastasized cancer with an anecdotal account from a large animal veterinary context: fenbendazole, used for parasitic infections in animals, purportedly cured cancer in mice in that story, and the speaker credits starting fenbendazole with achieving an all-clear status several months later.

Fenbendazole is described as more than just a dog dewormer, comparing that description to saying water is only for lawns. It works on various animals, impacting cestodes, nematodes, flukes, and protozoa like giardia. Fenbendazole isn't approved for human use because research is done on animals, while its cousins, mebendazole and albendazole, are researched on humans. Joe Tippins, diagnosed with small cell lung cancer, was sent home with hospice after chemotherapy led to metastasis. Following a vet's advice, he took fenbendazole, and within three months, his scans were clear. Fenbendazole binds to microtubules, preventing mitosis and causing apoptosis, similar to taxanes and vinca alkaloids. It arrests cells, upregulates tumor suppressor genes like p53 and p21, and is similar to metformin in glucose control. It inhibits hexokinase two, which is upregulated in cancers to increase glucose uptake. It also helps the immune system recognize tumors and reverses tumor-associated macrophages.

Diets can reduce glucose, but not glutamine, an essential amino acid for tumor cells, the immune system, gut health, and the urea cycle. Normal immune cells and neoplastic tumor cells use the same fuel. The "press pulse" strategy manages cancer by consistently pressing glucose down via a transition to ketones, while drugs pulse glutamine. Aggressively targeting glutamine compromises the immune system, leading to infections. Small doses of glutamine-targeting drugs are used briefly once the patient is in therapeutic ketosis, then removed to allow the immune system and gut to recover. Immune cells are stunned, not killed, by glutamine deprivation, reactivating to clear dead cancer cells once the drug is removed. Adding glutamine back can rescue some tumor cells, but their growth is slow due to the glucose restriction. After immune system recovery, another small dose of glutamine inhibitor is administered, slowly degrading the tumor while the rest of the body becomes healthier.

Ivermectin, the controversial anti-parasitic drug, has shown potential in stopping the growth or killing certain cancer cells. Research suggests that it may be effective against various types of cancer, including breast, prostate, stomach, colon, liver, lung, kidney, and leukemia. Ivermectin induces apoptosis, or natural cell death, in cancer cells. It is even being used alongside chemotherapy for breast cancer. However, it is important to consult with your doctor before considering Ivermectin for any purpose. For more information on fighting cancer, you can watch a lecture by Dr. Shintani at ehealthandu.com. This is Dr. Chintani, a board-certified MD and nutritionist trained at Harvard, signing off for your health.

Fenbendazole, a potential cancer drug, has at least 12 proven anti-cancer mechanisms. It disrupts microtubule polymerization, induces cell cycle arrest, blocks glucose transport, increases tumor suppressor levels, inhibits cancer cell viability and migration, induces apoptosis and autophagy, inhibits angiogenesis and drug resistance, and sensitizes cells to chemo and radiation therapy. Mebendazole, a similar drug, is already in clinical trials for brain and colon cancers. However, there are no clinical trials for Fenbendazole, possibly because it is cheap, safe, and effective. Big pharma may not see a profit in it. This raises concerns about withholding information and preventing people from using potentially beneficial treatments. The current society seems to promote sickness, allowing big pharma to profit from remedies.

A scientist at Merck Animal Health implanted cancer in mice for research. The mice also developed intestinal parasites, so she gave them Fenbendazole, a drug used to kill parasites. Surprisingly, the mice were cured of cancer. Inspired by this, a man with stage 4 glioblastoma started taking Fenbendazole, a dog dewormer, and mixed it with yogurt or smoothies. He bought it online without a prescription. He also added curcumin, CBD oil, and vitamin E to his regimen. This unconventional treatment is now known as the Joe Tippen's protocol.